# Observational Study of Nivolumab Monotherapy or in Combination With Ipilimumab in Participants With Advanced Melanoma and in Participants With Adjuvant Nivolumab Therapy

> **NCT02990611** · — · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 1087 (actual)

## Conditions studied

- Melanoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02990611
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-06
- **Primary completion:** 2025-06-20
- **Final completion:** 2025-06-20
- **Target enrollment:** 1087 (ACTUAL)
- **Last updated:** 2025-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02990611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02990611, "Observational Study of Nivolumab Monotherapy or in Combination With Ipilimumab in Participants With Advanced Melanoma and in Participants With Adjuvant Nivolumab Therapy". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02990611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*